Management of opportunistic infections complicating the acquired immunodeficiency syndrome.
Therapy of opportunistic infection in patients with the acquired immunodeficiency syndrome is frustrating, and there is no convincing evidence that aggressive treatment and/or prophylaxis other than for Pneumocystis infection can significantly prolong life. While much clinical effort is expended on treating sequential life-threatening infections, the overall course is usually progressively downhill. Thus, any real impact on the disease should be aimed at the causative viral agent, because it is destruction of a critical component of the immune system that predisposes to opportunistic infections.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000382:microbiology; D000328:Adult; D002177:Candidiasis / Q000209:etiology; D003453:Cryptococcosis / Q000209:etiology; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000209:etiology; D008297:Male; D009164:Mycobacterium Infections / Q000209:etiology; D009181:Mycoses / Q000209:etiology; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000209:etiology; D065227:Transfusion Reaction; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014777:Virus Diseases / Q000209:etiology
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole